Kinetics and regulation of cytochrome P450-mediated etoposide metabolism

Drug Metabolism and Disposition

Volumn 32, Issue 9, 2004, Pages 993-1000

  Zhuo, Xiaoliang ^a,c   Zheng, Naiyu ^a,c   Felix, Carolyn A ^b   Blair, Ian A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; ETOPOSIDE; ETOPOSIDE CATECHOL; ETOPOSIDE QUINONE; GYRASE INHIBITOR; MESSENGER RNA; MIXED LINEAGE LEUKEMIA PROTEIN; PAROXETINE; QUINONE DERIVATIVE; RECOMBINANT ENZYME; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG METABOLISM; DRUG STRUCTURE; ENZYME REGULATION; FEMALE; HUMAN; HUMAN TISSUE; KINETICS; LEUKEMIA; LIQUID CHROMATOGRAPHY; LIVER CELL; MALE; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REACTION ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STRUCTURE ANALYSIS; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; CYTOCHROME P-450 ENZYME SYSTEM; DNA TOPOISOMERASES, TYPE II; ETOPOSIDE; FEMALE; HEPATOCYTES; HUMANS; KINETICS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RIFAMPIN; RNA, MESSENGER; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBCELLULAR FRACTIONS; TENIPOSIDE;

EID: 4143090798     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ben-Yehuda D, Krichevsky S, Shafran S, Cohen SB, Goldschmidt N, Kedmi M, Neriah SB, and Rund D (2002) Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 patients. Blood 100:324a.
2. Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO, Behm FG, Camitta BM, Pui CH, et al. (2002) Genetic polymorphisms in CYP3A5, CYF3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 12:605-611.
3. Brown JM and Wouters BG (1999) Apoptosis, p53 and tumor cell sensitivity to anticancer agents. Cancer Res 59:1391-1399.
4. Bowen WP, Carey JE, Miah A, McMurray HF, Munday PW, James RS, Coleman RA, and Brown AM (2000) Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 28:781-788.
5. Chang TK, Yu L, Maurel P, and Waxman DJ (1997) Enhanced cyclophosphamide and ifosf-amide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 57:1946-1954.
6. Creaven PJ (1982) The clinical pharmacology of VM26 and VP16-213. A brief overview. Cancer Chemother Pharmacol 7:133-140.
7. Felix CA (1998) Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1400:233-255.
8. Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA, and Rebbeck TR (1998) Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 95:13176-13181.
9. Finta C and Zaphiropoulos PG (2000) The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 260:13-23.
10. Fortune JM and Osheroff N (2000) Topoisomemse II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64:221-253.
11. Grzanka A, Grzanka D, and Orlikowska M (2003) Cytoskeletal reorganization during process of apoptosis induced by cytostatic drugs in K-562 and HL-60 leukemia cell lines. Biochem Pharmacol 66:1611-1617.
12. Hande KR (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34:1514-1521.
13. Jounaidi Y, Guzelian PS, Maurel P, and Vilarem MJ (1994) Sequence of the 5′-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7. Biochem Biophys Res Commun 205:1741-1747.
14. Kawashiro T, Yamashita K, Zhao XJ, Koyama E, Tani M, Chiba K, and Ishizaki T (1998) A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 286:1294-1300.
15. Kishi S, Yang W, Boureau B, Morand S, Das S, Chen P, Cook EH, Rosner GL, Schuetz E, Pui CH, and Relling MV (2004) Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103:67-72.
16. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
17. LeCluyse EL (2001) Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343-368.
18. Liu N, Zhang QY, Vakharia D, Dunbar D, and Kaminsky LS (2001) Induction of CYP1A by benzo[k]fluoranthene in human hepatocytes: CYPIA1 or CYPIA2? Arch Biochem Biophys 389:130-134.
19. Lovett BD, Lo NL, Rappaport EF, Blair IA, Osheroff N, Zheng N, Megonigal MD, Williams WR, Nowell PC, and Felix CA (2001a) Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4; 11) translocation. Proc Natl Acad Sci USA 98:9802-9807.
20. Lovett BD, Strumberg D, Blair IA, Pang S, Burden DA, Megonigal MD, Rappaport EF, Rebbeck TR, Osheroff N, Pommier YG, and Felix CA (2001b) Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry 40:1159-1170.
21. Mans DR, Retel J, van Maanen JM, Lafleur MV, van Schaik MA, Pinedo HM, and Lankelma J (1990) Role of the semi-quinone free radical of the anti-tumor agent etoposide (VP-16-213) in the inactivation of single- and double-stranded phi X174 DNA. Br J Cancer 62:54-60.
22. McLeod HL and Evans WE (1993) Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. Cancer Surv 17:253-268.
23. Pang S, Zheng N, Felix CA, Scavuzzo J, Boston R, and Blair IA (2001) Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 36:771-781.
24. Raucy JL (2003) Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 31:533-539.
25. Relling MV, Evans R, Dass C, Desiderio DM, and Nemec J (1992) Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther 261:491-496.
26. Relling MV, Nemec J, Schuetz EG, Schuetz JD, Gonzalez FJ, and Korzekwa KR (1994) O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 45:352-358.
27. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 29:413-580.
28. Schuetz E, Lan L, Yasuda K, Kim R, Kocarek TA, Schuetz J, and Strom S (2002) Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents. Mol Pharmacol 62:439-445.
29. Sinkule JA (1984) Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmacotherapy 4:61-73.
30. van Maanen JM, Retel J, de Vries J, and Pinedo HM (1988) Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 80:1526-1533.
31. Westlind A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A4 expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761.
32. Whitmarsh RJ, Saginario C, Zhuo Y, Hilgenfeld E, Rappaport EF, Megonigal MD, Carrol M, Liu M, Osheroff N, Cheung NK, et al. (2003) Reciprocal DNA topoisomerase II cleavage events at 5′-TATTA-3′ sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(II) and der(9) genomic breakpoint junctions in treatment-related AML without further processing, Oncogene 22:8448-8459.
33. Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, Fujita K, and Kamataki T (2003) Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol 66:2333-2340.
34. Zheng N, Felix CA, Pang S, Boston R, Moate P, Scavuzzo J, and Blair IA (2004) Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide. Clin Cancer Res 10:2977-2985.